文献速递银屑病与炎症性皮肤病

司库奇尤单抗治疗中重度掌跖脓疱型银屑病:2PRECISE研究结果

Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
PubMed 文献 · J Am Acad Dermatol · 2019-02-01

2PRECISE是一项3b期随机双盲安慰剂对照研究,比较司库奇尤单抗300mg、150mg与安慰剂治疗中重度掌跖脓疱型银屑病52周。第52周300mg组PPPASI75应答率达41.8%,生活质量改善优于安慰剂,未观察到意外不良事件。

要点

  • 第52周300mg组PPPASI75应答率达41.8%,显示长期获益趋势。
  • 300mg组第16周DLQI 0/1应答率13.0% vs 安慰剂4.3%,生活质量改善更优。

核心结论

  • 司库奇尤单抗300mg治疗掌跖脓疱型银屑病在第16周主要终点未达到预设显著性水平(2.5%)。
  • 但300mg组在第52周PPPASI75应答率达41.8%,并显示生活质量改善,未观察到意外不良事件。

研究设计与样本

  • 2PRECISE为3b期多中心、随机、双盲、安慰剂对照、平行组研究,治疗观察52周。
  • 纳入中重度掌跖脓疱型银屑病患者,随机分为司库奇尤单抗300mg组(n=79)、150mg组(n=80)和安慰剂组(n=78)。

主要发现

  • 第52周300mg组PPPASI75应答率为41.8%。
  • 第16周300mg组DLQI 0/1应答率为13.0%,安慰剂组为4.3%。
  • 第52周300mg组DLQI 0/1应答率为43.1%。
  • 未观察到意外不良事件。

关键数值与推荐

  • 主要终点为第16周PPPASI75应答率,预设显著性水平为2.5%。
  • 第52周300mg组PPPASI75为41.8%,DLQI 0/1应答率为43.1%。
  • 第16周300mg组DLQI 0/1应答率为13.0% vs 安慰剂4.3%。

临床怎么用

  • 司库奇尤单抗300mg可作为中重度掌跖脓疱型银屑病的治疗选择之一,但需注意第16周主要终点未达预设显著性水平。
  • 治疗决策应结合长期应答(第52周PPPASI75 41.8%)和生活质量改善综合评估。
  • 治疗期间需监测不良事件,本研究未观察到意外安全性信号。

局限性

  • 样本量较小(300mg组79例、150mg组80例、安慰剂组78例)。
  • 掌跖脓疱型银屑病疾病病程特征可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms and/or soles that is resistant to treatment. Secukinumab, an anti-interleukin 17A monoclonal antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis. OBJECTIVE: The primary objective was to determine the rate of achievement of a 75% improvement from baseline in Palmoplantar Psoriasis Area and Severity Index (PPPASI75) with secukinumab at week 16 versus with placebo (at a 2.5% significance level). METHODS: 2PRECISE was a phase 3b multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing treatment with 300 mg of secukinumab (n = 79), 150 mg of secukinumab (n = 80), and placebo (n = 78) in subjects with moderate-to-severe PPP over a period of 52 weeks. RESULTS: The primary end point was not met. At week 16, 26.6% of subjects treated with 300 mg of secukinumab achieved PPPASI75 versus 14.1% of those who received placebo (P = .0411) (odds ratio, 2.62; 95% confidence interval, 1.04-6.60). At week 52, 41.8% of subjects treated with 300 mg of secukinumab had achieved ppPASI75. More Dermatology Life Quality Index responses of 0 or 1 were achieved with 300 mg of secukinumab (13.0%) than with placebo (4.3%) at week 16. At week 52, 43.1% of subjects receiving 300 mg of secukinumab had a Dermatology Life Quality Index response of 0 or 1. No unexpected adverse events were observed. LIMITATIONS: Small sample size and characteristics of the PPP disease course. CONCLUSION: Patients with PPP who were treated with secukinumab, 300 mg, showed benefit in terms of PPPASI75 responses over 52 weeks and improved quality of life.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. J Am Acad Dermatol. 2019. PMID: 30716404. doi:10.1016/j.jaad.2019.01.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。